Investment
Features
FeesSafety
Academy
More
Pluang+

Equity markets rally on AI optimism despite macro challenges and power grid concerns in Texas.

Market News
23 Sep 2026
Seeking Alpha
View Source
Neutral
Equity markets rally on AI optimism despite macro challenges and power grid concerns in Texas.

Equity markets have rebounded this week, driven mainly by optimism around artificial intelligence (AI) despite challenges like rising diesel prices and Federal Reserve rate hikes. OpenAI anticipates a $278 billion cash burn from 2026 to 2030, delaying its IPO to 2027 amid valuation uncertainties. Meanwhile, Texas has paused new AI data center permits due to power grid risks, potentially slowing AI infrastructure growth. Market valuations remain high and vulnerable if the AI growth story weakens.

The AI narrative and its market implications provide context for these figures from Pluang's Technology sector as of Sep 23, 2026 21:21 WIB: out of 150 priced US tech stocks, 51 rose and 98 fell. Notable movers include AEHR at USD 93.27 with a -7.29% change and a typical hold time of 13 days, FSLY at USD 24.27 down 6.92% with 26 days hold time, and RELY at USD 19.94 down 6.30% but with 100% buy order activity and a 52-day hold time.

More News

GE Aerospace stock could rise 35% as analysts highlight strong backlog and new engine orders.

GE Aerospace stock could rise 35% as analysts highlight strong backlog and new engine orders.

Jefferies analysts set a new price target of $435 for General Electric Aerospace, implying a 35% upside from its current price of around $321. GE Aerospace's strong position is supported by a $170 billion commercial services backlog and 80,000 aircra...

Analyst Insights
Bullish
2 hours ago
BNP Paribas cuts PepsiCo price target to $161, citing demand challenges but keeps Outperform rating.

BNP Paribas cuts PepsiCo price target to $161, citing demand challenges but keeps Outperform rating.

BNP Paribas lowered its price target for PepsiCo from $183 to $161 on September 23, 2026, due to ongoing demand challenges in North America. Despite the cut, the firm maintained an Outperform rating, indicating confidence in the stock's potential. Th...

Analyst Insights
Bearish
3 hours ago
Celldex's price target jumps to $88 after positive Phase III trial for chronic urticaria drug.

Celldex's price target jumps to $88 after positive Phase III trial for chronic urticaria drug.

Celldex Therapeutics saw its price target raised from $70 to $88 by Leerink Partners following successful Phase III trial results for its drug barzolvolimab treating chronic spontaneous urticaria (CSU). The trials met all primary endpoints, showing l...

Analyst Insights
Bullish
3 hours ago
Ero Copper stock holds steady with a raised price target amid plans to boost production by 2028.

Ero Copper stock holds steady with a raised price target amid plans to boost production by 2028.

Ero Copper, a major copper producer, shows stock volatility between $16.88 and $40.83 over the past year. Analyst firm CIBC maintained a "Neutral" rating but increased the price target to C$56.00, reflecting optimism about the company's long-term gro...

Analyst Insights
Bullish
3 hours ago
Cintas reports strong Q1 with EPS $1.39 and revenue up 10.9%, beating estimates.

Cintas reports strong Q1 with EPS $1.39 and revenue up 10.9%, beating estimates.

Cintas Corporation posted robust first-quarter results, surpassing analyst expectations with earnings per share of $1.39 and revenue of $3.01 billion, a 10.9% increase year-over-year. The company's organic revenue growth was 8.9%, reflecting solid bu...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App